Medical device company Nevro has received approval from the US Food and Drug Administration (FDA) and announced a limited market launch of its HFX iQ with HFX AdaptivAI, the AI-driven technology in spinal cord stimulation (SCS) for chronic pain treatment.
HFX AdaptivAI is designed to provide personalised and responsive pain relief. It optimises therapy over time, even when patients have achieved more than 50% pain relief.
Go deeper with GlobalData
The system’s Bipole Interlacing technology uses direct patient input to create custom therapy programmes in real-time, potentially reducing the frequency of device charging to as little as six times per year through its Smart Power feature.
The technology also provides enhanced real-time insights into quality-of-life metrics and device data, facilitating effective patient-clinician interactions. Patients can report pain relief more quickly compared to traditional programming methods.
Additionally, HFX AdaptivAI includes advanced proactive remote monitoring, allowing physicians to track their patients’ pain management journey through Nevro’s healthcare provider portal.
Nevro CEO and president Kevin Thornal said: “HFX AdaptivAI delivers personalised pain relief, utilising AI and leveraging millions of data points and ten years of innovation and patient care.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“We believe this new solution is a major milestone, and it demonstrates our dedication to freeing patients from the burden of chronic pain through evidence-based therapies that transform patients’ lives.
“Importantly, HFX AdaptivAI puts patients in control of their pain relief while, at the same time, providing physicians the ability to monitor their patient’s pain journey – closing the loop that matters.”
In December 2023, Nevro acquired Vyrsa Technologies for approximately $75m.
This acquisition is expected to further enhance Nevro’s capabilities in the development of advanced solutions for chronic pain management.
